Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand.
Eastern Marine and Coastal Resources Research and Development Center, Rayong, Thailand.
J Vet Pharmacol Ther. 2024 Jan;47(1):54-59. doi: 10.1111/jvp.13406. Epub 2023 Sep 16.
The pharmacokinetics were described of meloxicam (MLX) in green sea turtles (Chelonia mydas), following a single intravenous (i.v.) and intramuscular (i.m.) administrations at one of two dosages of 0.1 or 0.2 mg/kg body weight (b.w.). The sample of 20 green sea turtles was divided into four groups (n = 5) using a randomization procedure according to a parallel study design. Blood samples were collected at pre-assigned times up to 168 h. MLX in the plasma was cleaned-up and quantified using a validated high-performance liquid chromatography method with UV detection. The concentration of MLX in the experimental green sea turtles with respect to time was pharmacokinetically analyzed using a non-compartment model. MLX plasma concentrations were quantifiable for up to 72 and 120 h after i.v. at dosages of 0.1 and 0.2 mg/kg b.w., respectively, whereas it was measurable for up to 168 h after i.m. administration at both dosages. The long elimination half-life value of MLX (28 h) obtained in green sea turtles after i.v. administration was consistent with the quite slow clearance rate for both dosages. The average maximum concentration (C ) values of MLX were 1.05 μg/mL and 4.26 μg/mL at dosages of 0.1 and 0.2 mg/kg b.w., respectively, with their elimination half-life values being 37.26 h and 30.64 h, respectively, after i.m. administrations. The absolute i.m. bioavailability was approximately 110%. These results suggested that i.m. administration of MLX at a dosage of 0.2 mg/kg b.w. was likely to be effective for clinical use in green sea turtles (Chelonia mydas). However, further studies are needed to determine the pharmacodynamic properties and clinical efficacy of MLX for the treatment of inflammatory disease after single and multiple dosages.
本研究描述了绿海龟单次静脉（i.v.）和肌肉内（i.m.）注射 0.1 或 0.2mg/kg 体重（b.w.）两种剂量的美洛昔康（MLX）后的药代动力学特征。根据平行研究设计，通过随机化程序将 20 只绿海龟样本分为四组（n=5）。在预定时间内采集血样，时间长达 168 小时。采用经验证的高效液相色谱法结合紫外检测，对血浆中的 MLX 进行净化和定量。采用非房室模型对实验用绿海龟的 MLX 浓度-时间数据进行药代动力学分析。静脉注射 0.1 和 0.2mg/kg b.w.时，MLX 血浆浓度分别在 72 和 120 小时内可定量检测，而肌肉内注射两种剂量时，可在 168 小时内检测到。静脉注射后，绿海龟 MLX 的长消除半衰期（28 小时）值与两种剂量的清除率相当缓慢一致。静脉注射 0.1 和 0.2mg/kg b.w.时，MLX 的平均最大浓度（C ）值分别为 1.05μg/mL 和 4.26μg/mL，其消除半衰期值分别为 37.26 小时和 30.64 小时。肌肉内注射的绝对生物利用度约为 110%。这些结果表明，绿海龟肌肉内注射 0.2mg/kg b.w.的 MLX 剂量可能对临床应用有效。然而，需要进一步研究以确定 MLX 单次和多次剂量治疗炎症性疾病的药效学特性和临床疗效。
